WallStSmart

Galectin Therapeutics Inc (GALT)vsBeiGene, Ltd. (ONC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ONC leads profitability with a 10.7% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 54/100 (C-).

GALT

Avoid

19

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 3/9Altman Z: -34.27

ONC

Buy

54

out of 100

Grade: C-

Growth: 9.3Profit: 6.5Value: 5.7Quality: 7.0
Piotroski: 5/9Altman Z: 0.75
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for GALT.

ONCUndervalued (+80.3%)

Margin of Safety

+80.3%

Fair Value

$1785.72

Current Price

$347.48

$1438.24 discount

UndervaluedFair: $1785.72Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GALT1 strengths · Avg: 10.0/10
Debt/EquityHealth
-1.0410/10

Conservative balance sheet, low leverage

ONC3 strengths · Avg: 9.0/10
EPS GrowthGrowth
166.7%10/10

Earnings expanding 166.7% YoY

Debt/EquityHealth
0.229/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
29.6%8/10

Revenue surging 29.6% year-over-year

Areas to Watch

GALT4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$347.93M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

ONC2 concerns · Avg: 2.0/10
P/E RatioValuation
64.2x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.752/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : GALT

The strongest argument for GALT centers on Debt/Equity.

Bull Case : ONC

The strongest argument for ONC centers on EPS Growth, Debt/Equity, Revenue Growth. Revenue growth of 29.6% demonstrates continued momentum.

Bear Case : GALT

The primary concerns for GALT are Revenue Growth, EPS Growth, Market Cap.

Bear Case : ONC

The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 64.2x leaves little room for execution misses.

Key Dynamics to Monitor

GALT profiles as a value stock while ONC is a growth play — different risk/reward profiles.

ONC carries more volatility with a beta of 0.50 — expect wider price swings.

ONC is growing revenue faster at 29.6% — sustainability is the question.

ONC generates stronger free cash flow (596M), providing more financial flexibility.

Bottom Line

ONC scores higher overall (54/100 vs 19/100) and 29.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Galectin Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic, cancerous and other diseases. The company is headquartered in Norcross, Georgia.

Visit Website →

BeiGene, Ltd.

HEALTHCARE · BIOTECHNOLOGY · USA

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.

Visit Website →

Want to dig deeper into these stocks?